Integer Holdings Corporation reports news as a medical device contract development and manufacturing organization serving cardio and vascular, neuromodulation, and cardiac rhythm management markets. Company updates commonly cover sales trends, organic growth, product-line performance, adjusted earnings measures, debt and leverage, and outlook commentary tied to customer programs and new product activity.
Integer news also includes governance and capital-allocation developments, including board composition, shareholder engagement, share repurchase authorization, investor conference participation, and broader strategy updates. The company’s public identity includes the Greatbatch Medical and Lake Region Medical brands and engineering and manufacturing work for medical device customers.
Graham Corporation (NYSE: GHM) announced the appointment of Christopher J. Thome as Vice President - Finance and Chief Financial Officer, effective April 4, 2022. Thome joins from Allied Motion Technologies (NASDAQ: AMOT) with nearly 30 years of finance experience. CEO Daniel J. Thoren expressed optimism about Thome's expertise in financial controls and operational knowledge, which could enhance the company's growth potential in defense and energy sectors. Thome succeeds Jeffrey F. Glajch, who retired.
Integer Holdings Corporation (NYSE: ITGR) reported a strong financial performance for Q4 and FY 2021, highlighting a 16% increase in Q4 sales to $313 million and a 14% increase in full-year sales to $1.221 billion. GAAP income from continuing operations rose by 30% in Q4, reaching $20 million, while full-year GAAP income climbed by 20% to $93 million. The company completed the acquisition of Oscor Inc. in December 2021, contributing to a total debt increase of $197 million to $828 million. Looking ahead, Integer projects sales growth of 10% to 12% for 2022.
Integer Holdings Corporation (NYSE:ITGR) will announce its financial results for Q4 and full year 2021 on February 17, 2022, at 7 a.m. CT. A webcast will follow at 8 a.m. CT to discuss these results and potential forward-looking information. Investors can access the call via domestic and international dial-in numbers or register for the webcast through the provided link. Integer specializes in medical device outsourcing and develops innovative technologies across various healthcare sectors.
Integer Holdings Corporation (ITGR) has successfully acquired Oscor, Inc., enhancing its portfolio in cardiovascular and neurostimulation markets. This acquisition adds specialized medical devices including venous access systems and diagnostic catheters, expanding Integer's product offerings and low-cost manufacturing capacity in the Dominican Republic. The deal is expected to strengthen customer relationships and foster growth through increased R&D capabilities. Oscor, with a legacy of over 40 years in electrophysiology, will significantly enhance Integer's market presence.
Integer Holdings Corporation (NYSE:ITGR) reported a 30% increase in sales for Q3 2021, reaching $306 million. However, GAAP net income fell 27% to $22 million, while non-GAAP adjusted net income surged 109% to $35 million. The company announced the acquisition of Oscor, Inc. for $220 million, which is expected to close in December 2021, enhancing Integer’s product offerings. 2021 sales outlook has been raised, projecting 12% to 14% growth. Integer aims for $200 to $250 million in annual capital for strategic acquisitions.
Integer Holdings Corporation (NYSE:ITGR) will release its Q3 2021 financial and operational results on October 28, 2021, at 7 a.m. CT. A conference call will follow at 8 a.m. CT to discuss these results and any significant forward-looking information. The call can be accessed via domestic and international numbers, with a conference ID of 7357789. An audio replay will be available for seven days post-call. Integer is a leading medical device outsource manufacturer, with a focus on cardiac and neuromodulation technologies.
Integer Holdings Corporation (NYSE: ITGR) announced plans to expand its operations in Galway, Ireland, by constructing a 60,000 square foot Medical Device Innovation and Manufacturing facility. This $30 million investment aims to meet rising demand for medical devices, particularly catheters and delivery systems. The new facility is expected to create 100-200 jobs and enhance R&D capabilities. Construction is slated to begin in 2022, with completion anticipated by late 2023. Integer currently employs around 1,300 people in Ireland, with 350 in Galway.
Integer Holdings Corporation (NYSE: ITGR) has announced a successful refinancing of its debt through the establishment of $1 billion in Senior Secured Credit Facilities. The new five-year $400 million Revolving Credit Facility, $250 million Term Loan A, and seven-year $350 million Term Loan B are expected to enhance operational flexibility and reduce borrowing costs. This transaction will improve future annualized diluted earnings per share by approximately $0.15 and extend the nearest debt maturity from 2022 to 2026.
Both Moody's and S&P upgraded the company's credit ratings to Ba3/BB- following this restructuring.
Integer Holdings Corporation (NYSE: ITGR) will showcase its innovative medical device outsourcing capabilities at the MD&M West Exposition in Anaheim, California, from August 10-12, 2021. At booth #2951, Integer will highlight its advanced Xcellion® Rechargeable Batteries, which reduce charging time by up to 70% and increase runtime by 30%. The company will also present its expanded laser cutting capabilities and comprehensive lead solutions. Integer emphasizes its commitment to quality and innovation in the medical device industry.
Integer Holdings Corporation (NYSE:ITGR) reported a strong financial performance for Q2 2021, with sales increasing by 30% to $312 million. GAAP net income rose by $29 million, reaching $29 million, while non-GAAP adjusted net income surged by 239% to $36 million. The company reduced total debt by $63 million to $669 million, achieving a leverage ratio of 3.1 times adjusted EBITDA. Looking ahead, Integer has raised its full-year sales growth outlook to 12-14% and expects adjusted operating income growth between 25-36%, signaling a robust recovery from the pandemic.